CytomX Therapeutics, Inc. (CTMX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 20M 40M 60M Q3 '16: 3.5M Q4 '16: 6.3M Q1 '17: 11.7M Q2 '17: 8.8M Q3 '17: 24.1M Q4 '17: 27.1M Q1 '18: 14.2M Q2 '18: 21.3M Q3 '18: 12.5M Q4 '18: 11.5M Q1 '19: 29.5M Q2 '19: 9M Q3 '19: 10.7M Q4 '19: 8.3M Q1 '20: 49.6M Q2 '20: 16.6M Q3 '20: 17.8M Q4 '20: 7.1M Q1 '21: 16M Q2 '21: 16.3M Q3 '21: 17.6M Q4 '21: 11.1M Q1 '22: 9M Q2 '22: 12.9M Q3 '22: 11.1M Q4 '22: 20.1M Q1 '23: 23.5M Q2 '23: 24.7M Q3 '23: 26.4M Q4 '23: 26.6M Q1 '24: 41.5M Q2 '24: 25.1M Q3 '24: 33.4M Q4 '24: 38.1M Q1 '25: 50.9M Q2 '25: 18.7M Q3 '25: 6M Q4 '25: 663K Q1 '26: 10.3M Q2 '26: 1.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '16: -14.9M Q4 '16: -14.2M Q1 '17: -8.6M Q2 '17: -25.4M Q3 '17: -11M Q4 '17: -1.2M Q1 '18: -15.6M Q2 '18: -13.3M Q3 '18: -23.2M Q4 '18: -25.8M Q1 '19: -16.6M Q2 '19: -31.2M Q3 '19: -25.7M Q4 '19: -68M Q1 '20: -2.8M Q2 '20: -16.1M Q3 '20: -14.9M Q4 '20: -24.1M Q1 '21: -15.6M Q2 '21: -19.2M Q3 '21: -22.6M Q4 '21: -34.9M Q1 '22: -32.1M Q2 '22: -30.1M Q3 '22: -29.7M Q4 '22: -9.5M Q1 '23: -5.7M Q2 '23: -3.3M Q3 '23: 3.1M Q4 '23: -606K Q1 '24: 11.7M Q2 '24: -8.5M Q3 '24: 4.1M Q4 '24: 17.7M Q1 '25: 22.6M Q2 '25: -1.3M Q3 '25: -15.8M Q4 '25: -27.9M Q1 '26: -19.7M Q2 '26: -23.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '16: -14.7M Q4 '16: -14M Q1 '17: -8.3M Q2 '17: -25.2M Q3 '17: -10.2M Q4 '17: 621K Q1 '18: -15.5M Q2 '18: -13.4M Q3 '18: -23.4M Q4 '18: -32.2M Q1 '19: -14.1M Q2 '19: -29M Q3 '19: -23.7M Q4 '19: -35.5M Q1 '20: 12.2M Q2 '20: -15.7M Q3 '20: -14.7M Q4 '20: -24M Q1 '21: -15.6M Q2 '21: -19.2M Q3 '21: -22.6M Q4 '21: -34.8M Q1 '22: -32M Q2 '22: -29.5M Q3 '22: -29.1M Q4 '22: -8.8M Q1 '23: -3.3M Q2 '23: -1.1M Q3 '23: 3M Q4 '23: 837K Q1 '24: 13.8M Q2 '24: -6.5M Q3 '24: 5.7M Q4 '24: 18.9M Q1 '25: 23.5M Q2 '25: -154K Q3 '25: -14.2M Q4 '25: -26.5M Q1 '26: -18.2M Q2 '26: -20.7M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-60M 0 60M 120M 180M Q3 '16: -14.2M Q4 '16: 1.9M Q1 '17: -19.1M Q2 '17: 173.2M Q3 '17: -5.7M Q4 '17: 22M Q1 '18: -14.6M Q2 '18: -26.6M Q3 '18: -5.6M Q4 '18: -28.7M Q1 '19: -39M Q2 '19: -48.7M Q3 '19: -23.3M Q4 '19: -29.5M Q1 '20: -49.7M Q2 '20: 97.1M Q3 '20: -24.7M Q4 '20: -17.4M Q1 '21: -29.9M Q2 '21: -28.2M Q3 '21: -29.7M Q4 '21: -31.2M Q1 '22: -41.3M Q2 '22: -34.2M Q3 '22: -33.8M Q4 '22: -1.4M Q1 '23: 9.3M Q2 '23: -25.2M Q3 '23: -18.2M Q4 '23: -22M Q1 '24: -26M Q2 '24: -19.5M Q3 '24: -20.7M Q4 '24: -19.9M Q1 '25: -21M Q2 '25: -15.8M Q3 '25: -15.5M Q4 '25: -23.2M Q1 '26: -25.5M Q2 '26: -18.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-60M 0 60M 120M 180M Q3 '16: -15M Q4 '16: 1.3M Q1 '17: -20M Q2 '17: 172.9M Q3 '17: -5.8M Q4 '17: 21.8M Q1 '18: -15.4M Q2 '18: -27.5M Q3 '18: -6.6M Q4 '18: -29.9M Q1 '19: -40.9M Q2 '19: -49M Q3 '19: -23.9M Q4 '19: -30.2M Q1 '20: -50.8M Q2 '20: 97.1M Q3 '20: -25.5M Q4 '20: -17.9M Q1 '21: -30.9M Q2 '21: -28.3M Q3 '21: -30M Q4 '21: -31.4M Q1 '22: -42M Q2 '22: -34.6M Q3 '22: -34.3M Q4 '22: -1.6M Q1 '23: 9.3M Q2 '23: -25.7M Q3 '23: -18.3M Q4 '23: -22.2M Q1 '24: -26.2M Q2 '24: -19.6M Q3 '24: -20.7M Q4 '24: -20M Q1 '25: -21.2M Q2 '25: -15.8M Q3 '25: -15.7M Q4 '25: -23.4M Q1 '26: -25.5M Q2 '26: -18.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 80M 160M 240M Q1 '19: 45.1M Q1 '20: 47M Q2 '20: 46.1M Q3 '20: 46.2M Q4 '20: 46.6M Q1 '21: 61M Q2 '21: 65.1M Q3 '21: 65.2M Q4 '21: 65.3M Q1 '22: 65.4M Q2 '22: 65.5M Q3 '22: 65.9M Q1 '23: 66.2M Q2 '23: 66.5M Q3 '23: 81M Q1 '24: 82.6M Q2 '24: 84.9M Q3 '24: 85.2M Q1 '25: 87.2M Q2 '25: 129.1M Q3 '25: 165M Q1 '26: 177.3M Q2 '26: 218.9M Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45.00 -30.00 -15.00 0.00 15.00 30.00 45.00 Q2 '15: -25.19 Q3 '15: -34.59 Q4 '15: -4.90 Q1 '16: 2.22 Q2 '16: 9.39 Q3 '16: 23.25 Q4 '16: -1.62 Q1 '17: -1.41 Q2 '17: -1.71 Q2 '15 Q4 '15 Q2 '16 Q4 '16 Q2 '17

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.